Proteomedix appoints new CEO to launch their diagnostic test


Proteomedix’ first product, a blood based prostate cancer test panel and risk score, will be introduced to the market early 2020. Before the lauch Helge Lubenow has been appointed as as Chief Executive Officer succeeding co-founder Ralph Schiess.


The board of directors of Proteomedix has appointed Helge Lubenow (picture) as Chief Executive Officer effective January 1, 2020. Helge Lubenow ideally complements the management team including Christian Brühlmann COO/ CFO and Ralph Schiess CSO who co-founded Proteomedix and translated the original biomarker panel into a CE-IVD marked and market-ready product. She brings a wealth of leadership and operating experience to Proteomedix. Currently she serves on the board of directors of several companies including Epigenomics AG, Indical Biosciences and Human Gesellschaft für Biochemika und Diagnostika. From 1997 to 2015 she was with QIAGEN, where she most recently led the diagnostics division as Senior Vice President Molecular Diagnostics. She holds a Ph.D. degree in Genetics from the University of Cologne, Germany “Proteomedix is strongly positioned to greatly improve prostate cancer diagnostic triage and Helge is the ideal person to shape the company`s transformation to a commercial stage organization. Helge brings over 20 years of diagnostics industry experience and has a proven track record driving value creation in cancer diagnostics" commented Werner Schäfer, Chairman of the Board of Directors of Proteomedix. "I am very excited to lead Proteomedix," said Helge Lubenow. "The company is uniquely positioned to play a major role in non-invasive cancer detection and I am thrilled to have the opportunity to build a leading commercial organization and accelerate market adoption of its tests." Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnostics. The company has identified novel biomarker signatures with utility in prostate cancer diagnostics, prognostics and therapy management. Their lead product Proclarix is a blood based prostate cancer test panel and risk score and will be introduced to the market early 2020. (Press release)